6-Benzyloxy-naphthalene-2-carboxamidine | 32048-12-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-Benzyloxy-naphthalene-2-carboxamidine
• 英文别名: 6-(Phenylmethoxy)-2-naphthalenecarboximidamide；6-phenylmethoxynaphthalene-2-carboximidamide
• CAS: 32048-12-7
• 化学式: C₁₈H₁₆N₂O
• 分子量: 276.338
• InChiKey: NYFFPKFXMHVBQE-UHFFFAOYSA-N

物化性质

• 沸点：
  470.3±37.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  59.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-(benzyloxy)-2-naphthonitrile 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 6-Benzyloxy-naphthalene-2-carboxamidine
  参考文献：
  名称：

  Wagner; Lischke; Markwardt, Pharmazie, 1977, vol. 32, # 12, p. 761 - 763

  摘要：

  DOI：

文献信息

• [EN] SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS<br/>[FR] PROMÉDICAMENTS D'AMIDOXINE INHIBITEURS DE LA SPHINGOSINE KINASE
  申请人：THORPE STEVEN BRANDON

  公开号：WO2017172989A1

  公开（公告）日：2017-10-05

  Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.

  鞘氨醇激酶是催化鞘氨醇-1-磷酸酯生物合成的酶。本发明提供了根据本文所述的公式(I)有效抑制鞘氨醇激酶1型、鞘氨醇激酶2型或两者的化合物的前药。公式I化合物在治疗一系列疾病中是有用的，其中在血液中增加鞘氨醇-1-磷酸酯水平在医学上是指示的。本发明还提供了公式I化合物的药物组合物。
• Polysubunit opioid prodrugs resistant to overdose and abuse
  申请人：Elysium Therapeutics, Inc.

  公开号：US10251878B2

  公开（公告）日：2019-04-09

  The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.

  本发明提供了治疗或预防疼痛的组合物和方法。 本发明提供的构建物在按处方口服时，可通过特定胃肠道酶的水解直接或间接释放阿片类药物。 胃肠道酶介导的阿片类药物从本发明构建物中的释放被设计为在摄入过量时通过饱和或抑制机制在体内减弱。 本发明进一步提供了对口服过量、化学篡改和非口服给药途径滥用具有高度耐受性的构建物。
• Sphingosine kinase inhibitor amidoxime prodrugs
  申请人：University of Virginia Patent Foundation

  公开号：US11180489B2

  公开（公告）日：2021-11-23

  Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.

  鞘氨醇激酶是催化鞘氨醇-1-磷酸的生物合成的酶。本发明提供了有效抑制鞘氨醇激酶 1 型、鞘氨醇激酶 2 型或二者的化合物原药，如本文所述的式 (I)。式 I 化合物可用于治疗一系列疾病，在这些疾病中，提高血液中鞘磷脂-1-磷酸的水平具有医学指征。本发明还提供了式 I 化合物的药物组合物。
• SPHINGOSINE KINASE INHIBITORS
  申请人：LYNCH Kevin R.

  公开号：US20170298032A1

  公开（公告）日：2017-10-19

  Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both. Certain compounds are selective for sphingosine kinase type 2 relative to sphingosine kinase type 1. Compounds of the invention can be used in treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. Diseases that can be treated by administration of an effective dose of a compound of the invention include a neoplastic disease that involves excess vascular growth; macular degeneration or diabetic retinopathy; an allergic disease such as asthma, an inflammatory disease of the eye such as uveitis, scleritis, or vitritis; an inflammatory disease of the kidney; a fibrotic disease; atherosclerosis; or pulmonary arterial hypertension. A compound of the invention can be used to improve the integrity of a vascular barrier in a disease where the vascular barrier is disrupted, such as cancer or Alzheimer's disease.
• SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS
  申请人：University of Virginia Patent Foundation

  公开号：US20200308159A1

  公开（公告）日：2020-10-01

  Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.